

From: [Director PTABDecision Review](#)
To: eellison-ptab@sternekessler.com; jkushan@sidley.com; ichagnon-ptab@sternekessler.com; dkappos@cravath.com; blaine.hackman@dechert.com; ahaddach@halozyme.com; dholman-ptab@sternekessler.com; jmack@halozyme.com; tliu-ptab@sternekessler.com; amy.mahan@sidley.com; tpowers-ptab@sternekessler.com; laurenmartin@quinnemanuel.com; lpazica-ptab@sternekessler.com; mark.stewart@merck.com; pkhanduri-ptab@sternekessler.com
Subject: IPR2026-00312, 00313, 00314, Merck Sharp & Dohme LLC v. Halozyme, Inc. Director Review Requests
Date: Friday, October 9, 2026 8:27:00 PM

Counsel,

Patent Owner's request for Director Review has been received in the above-referenced case. Petitioner is authorized to submit a response limited to the issues raised in the Director Review request, of no more than 15 pages, to be filed within five business days of this email. Any such response must be filed in P-TACTS, i.e., by selecting the "Other: Other" paper type and the paper must be titled "Authorized Response to Director Review Request" or it may not be considered. No new evidence is permitted. No further briefing is authorized at this time.

The Director will determine whether review will be granted or denied and the parties will be notified of the result of the Director Review request.

Thank you.

IPR2026-00312, 00313, and 00314
Ex. 3100